Real-world evidence (RWE) in medicine is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of real-world data (RWD). RWE can be generated by different study designs or analyses, including but not limited to, randomized trials, including large simple trials, pragmatic trials, and retrospective or prospective observational studies.[1] In the USA the 21st Century Cures Act required the FDA to expand the role of real world evidence.[2]
Real-world evidence comes into play when clinical trials cannot really account for the entire patient population of a particular disease. Patients with comorbidities or belonging to a distant geographic region or age limit who did not participate in any clinical trial may not respond to the treatment in question as expected. RWE provides answers to these problems and also to analyze effects of drugs over a longer period of time. Pharmaceutical companies and health insurance payers study RWE to understand patient pathways to deliver appropriate care for appropriate individuals and to minimize their own financial risk by investing on drugs that work for patients.[3]
Data quality edit
Data quality (DQ) is the degree to which a given dataset meets a user's requirements. In the primary healthcare setting, poor quality data can lead to poor patient care, negatively affect the validity and reproducibility of research results and limit the value that such data may have for public health surveillance.[4]
In order to use real-world data to generate evidence, data must be of sufficient quality. Kahn et al. define data quality as consisting of three components: (1) conformance (do data values adhere to do specified standard and formats?; subtypes: value, relational and computational conformance); (2) completeness (are data values present?); and (3) plausibility (are data values believable?; subtypes uniqueness, atemporal; temporal).[5] Sometimes, data reliability and data quality are used interchangeably.
Fitness for purpose edit
Similarly to having sufficient data quality, the real-world data must be fit for purpose. An RWD resource can be fit for addressing some questions, but not others. For example, a dataset that lacks mother-to-baby links may not be appropriate to address drug risk for fetus but can be used for questions for drug safety in patients taking epilepsy treatment (limited to the patient; not including safety for fetus). Since data quality can be evaluated outside a particular purpose (on a general level), fitness for purpose is evaluated separate from data quality and is not included in the concept of data quality.* Real-World Evidence — What Is It and What Can It Tell Us? The New England Journal of Medicine, December 6, 2016.[6][7]
See also edit
References edit
- ^ "Real-World Evidence". www.fda.gov. Retrieved 2022-09-19.
- ^ "Text - H.R.34 - 114th Congress (2015-2016): 21st Century Cures Act | Congress.gov | Library of Congress".
- ^ Commissioner, Office of the (April 25, 2023). "Real-World Evidence". FDA.
- ^ Ehsani-Moghaddam B, Martin K, Queenan JA (2021). "Data quality in healthcare: A report of practical experience with the Canadian Primary Care Sentinel Surveillance Network data". Health Information Management Journal. 50 (1–2): 88–92. doi:10.1177/1833358319887743. PMID 31805788. S2CID 208743562.
- ^ Kahn MG, Callahan TJ, Barnard J, Bauck AE, Brown J, Davidson BN, Estiri H, Goerg C, Holve E, Johnson SG, Liaw ST, Hamilton-Lopez M, Meeker D, Ong TC, Ryan P, Shang N, Weiskopf NG, Weng C, Zozus MN, Schilling L (2016). "A Harmonized Data Quality Assessment Terminology and Framework for the Secondary Use of Electronic Health Record Data". eGEMs. 4 (1): 1244. doi:10.13063/2327-9214.1244. PMC 5051581. PMID 27713905.
- ^ Mahajan, Rajiv. “Real World Data: Additional Source for Making Clinical Decisions.” International Journal of Applied and Basic Medical Research 5.2 (2015): 82. PMC. Web. 5 May 2018
- ^ Berger, Marc L. et al. “Good Practices for Real‐world Data Studies of Treatment And/or Comparative Effectiveness: Recommendations from the Joint ISPOR‐ISPE Special Task Force on Real‐world Evidence in Health Care Decision Making.” Pharmacoepidemiology and Drug Safety 26.9 (2017): 1033–1039. PMC. Web. 5 May 2018.